Molecular classification of endometrial cancer: Impact on adjuvant treatment planning
The data suggest that the new molecular classification, that is, testing for POLE mutation, MSI, and p53 mutation and for endometrial carcinoma, is a valuable tool for the recurrence risk prognosis and improved planning of adjuvant treatment for EC.
Authors
- Dimitrios Zouzoulas (ORCID: https://orcid.org/0000-0003-2518-5657)
- Eleni T. Timotheadou (ORCID: https://orcid.org/0000-0003-2545-8926)
- Grigoris Grimbizis (ORCID: https://orcid.org/0000-0002-6230-4638)
- Stavroula Pervana
- Panagiotis M Tzitzis (ORCID: https://orcid.org/0000-0002-0362-5749)
- Μαρία Τοπαλίδου
- Iliana Sofianou
- Dimitrios Tsolakidis (ORCID: https://orcid.org/0000-0002-6608-509X)
Institutions
- Aristotle University of Thessaloniki (GR)
- Papageorgiou General Hospital (GR)
Publication Details
- Journal
- CytoJournal
- Published
- 2024-11-21
- DOI
- https://doi.org/10.25259/cytojournal_37_2024
- Citations
- 3
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.75